OSLM

Outcome Studies
in Laboratory Medicine

guest

👤

Learn more about this platform

Publication

Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study.

Journal : Clinics and research in hepatology and gastroenterology
Authors : Petitdidier N, Beaugerie L, Carbonnel F, Bourrier A, Treton X, Rajca S, Malamut G, Abitbol V, Allez M, Pelletier AL, Marthey L, Jouet P, Benamouzig R, Amiot X, Bouhnik Y, Amiot A

b

Open in PubMed
p
c
10.1016/j.clinre.2019.11.008 : DOI
31924554 : PMID

Background

Whether therapeutic drug monitoring (TDM) of infliximab should be implemented in daily practice is an ongoing controversy.

Aims

To assess the real-world use of TDM in an observational multicentre cohort study with consecutive patients with inflammatory bowel disease (IBD) treated with CT-P13.

Methods

Between September 2015 and December 2016, 364 patients with IBD were treated with CT-P13 in 13 gastroenterology departments and were followed up for 54 weeks. Disease activity, CT-P13 trough concentration and anti-CT-P13 antibody (ACA) were recorded.

Results

Steroid-free clinical remission rates at week 54 were 67.0% and 56.4% in patients with CD and UC, respectively. CT-P13 trough concentrations were measured in 70.7% of the patients. The mean CT-P13 trough concentration was 4.2±4.3μg/mL. The presence of ACA was observed in 53 (15.9%) patients. CT-P13 trough concentration was collected in a proactive approach in 62.8% of cases and in a reactive approach in 37.2%. Among patients who submitted to TDM, CT-P13 therapy was optimized in 88.7% of the reactive group and in 22.5% of the proactive group (P<0.001).

Conclusion

In a real-world cohort of patients with IBD treated with CT-P13, more than two-thirds of the patients underwent TDM. CT-P13 optimization was much less common in the proactive approach than in the reactive approach.